アブストラクト
| Title | 4. ギラン・バレー症候群 / フィッシャー症候群 (1) 診断・治療と今後の展望 |
|---|---|
| Subtitle | 特集 免疫性神経疾患 update - 基礎・臨床研究の最新知見 - III. 診断と治療 |
| Authors | 内堀歩, 千葉厚郎 |
| Authors (kana) | |
| Organization | 杏林大学 脳神経内科 |
| Journal | 日本臨牀 |
| Volume | 78 |
| Number | 11 |
| Page | 1881-1887 |
| Year/Month | 2020 / 11 |
| Article | 報告 |
| Publisher | 日本臨牀社 |
| Abstract | 「はじめに」ギラン・バレー症候群(Guillain-Barre syndrome:GBS)は代表的な免疫性末梢神経障害であり, 先行感染を契機に発症する頻度が高く, 急速に進行する弛緩性運動麻痺がみられる. 発症から4週間以内に極期に達し, 臨床経過は単相性で8週間を超えて進行することはなく, 極期を過ぎると快方に向かう. 両側性弛緩性運動麻痺を中核症状として, 軽度の感覚障害を伴う典型的な症例のほか, 限局した機能障害を呈する純粋運動型や純粋感覚型, 純粋自律神経型などがある. また, 障害の分布が特異な病型として, 運動失調・眼球運動障害・腱反射低下を三徴とするフィッシャー症候群(Fisher syndrome:FS), 咽頭頸部上腕型(pharyngeal-cervical-brachial:PCB)などは臨床亜型と認識されている. |
| Practice | 医学総合 |
| Keywords | Guillain-Barre syndrome, Fisher syndrome, diagnosis, treatment, Ca2+ -dependent antibody |
- 全文ダウンロード： 従量制、基本料金制の方共に1,243円(税込) です。
参考文献
- 1) 楠 進, ほか:GBS疫学調査研究グループ. GBS疫学調査:本邦における脱髄型, 軸索型の頻度および臨床的特徴. 平成23年免疫性神経疾患に関する調査研究 総括・分担研究報告書. p151-153,2011.
- 2) Hughes RA, Cornblath DR:Guillain-Barre syndrome. Lancet 366:1653-1666,2005.
- 3) Mori M, et al:Clinical features and prognosis of Miller Fisher syndrome. Neurology 56:1104-1106,2001.
- 4) Koike H:[Zika Virus and Guillain-Barre Syndrome]. Brain Nerve 70:113-120,2018.
- 5) Paterson RW, et al:The emerging spectrum of COVID-19 neurology:clinical, radiological and laboratory findings. Brain, 2020.(DOI:10.1093/brain/awaa240)
残りの15件を表示する
- 6) De Sanctis P, et al:Guillain Barre Syndrome associated with SARS-CoV-2 infection. A Systematic Review, 2020.(DOI:10.1111/ene.14462)
- 7) Asbury AK, Cornblath DR:Assessment of current diagnostic criteria for Guillain-Barre syndrome. Arm Nevlrol 27 Suppl:S21-24,1990.
- 8) Sejvar JJ, et al:Guillain-Barre syndrome and Fisher syndrome:case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29:599-612,2011.
- 9) Ho TW, et al:Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118(Pt 3):597-605,1995.
- 10) Hadden RD, et al:Electrophysiological classification of Guillain-Barre syndrome:clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 44:780-788,1998.
- 11) Kuwabara S, et al:Axonal involvement at the common entrapment sites in Guillain-Barre syndrome with IgG anti-GM1 antibody. Muscle Nerve 22:840-845,1999.
- 12) Kusunoki S, et al:Antibodies against gangliosides and ganglioside complexes in Guillain-Barre syndrome:new aspects of research. Biochim Biophys Acta 1780:441-444,2008.
- 13) Kaida K, et al:Ganglioside complexes as new target antigens in Guillain-Barre syndrome. Ann Neurol 56:567-571,2004.
- 14) Uchibori A, et al:Ca(2+)-dependent anti-GQ1b antibody in GQ1b-seronegative Fisher syndrome and related disorders. J Neuroimmunol 298:172-177,2016.
- 15) Altmann P, et al:Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barre syndrome. J Neuroinflammation 17:86,2020.
- 16) Verboon C, et al:Original research:Second IVIg course in Guillain-Barre syndrome with poor prognosis:the non-randomised ISID study. J Neurol Neurosurg Psychiatry 91:113-121,2020.
- 17) Walgaard C, et al:Second IVIg course in Guillain-Barre syndrome patients with poor prognosis(SID-GBS trial):Protocol for a double-blind randomized, placebo-controlled clinical trial. J Peripher Nerv Syst 23:210-215,2018.
- 18) Yamagishi Y, et al:Markers for Guillain-Barre syndrome with poor prognosis: a multi-center study. J Peripher Nerv Syst 22:433-439,2017.
- 19) Misawa S, et al:Safety and efficacy of eculizumab in Guillain-Barre syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 17:519-529,2018.
- 20) Wang Y, et al:IgG-degrading enzyme of Streptococcus pyogenes(IdeS)prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barre syndrome. Exp Neurol 291:134-140,2017.
